Group 1: AI Investment Opportunities - Artificial intelligence (AI) is generating excitement on Wall Street, presenting investors with attractive long-term opportunities [1] - Not all AI stocks are equally promising; the article evaluates three AI stocks, identifying two as attractive and one as less favorable [2] Group 2: Meta Platforms - Meta Platforms (NASDAQ: META) is heavily investing in AI, which is positively impacting its financial results, with strong revenue and earnings growth attributed to AI-driven engagement on its platforms [4] - The company is gathering more user data through deeper engagement, enabling targeted advertising campaigns, although its substantial AI investments have caused some investor concern, leading to a drop in share prices after its third-quarter earnings report [5] - Meta's ecosystem of over 3.5 billion daily active users presents numerous monetization opportunities beyond advertising, and its AI investments could lead to significant future revenue streams [7][8] Group 3: Apple - Apple (NASDAQ: AAPL) has not yet fully capitalized on AI compared to its peers, but the success of the iPhone 17, which includes various AI features, is driving a strong renewal cycle [11] - Revenue growth for Apple in the last two quarters is the highest in three years, with positive guidance suggesting continued improvement [11]

Core Insights - Lux Capital has closed a $1.5 billion ninth fund, marking the largest fund in the firm's history [1] - Despite a decline in new VC funds raised in the U.S. to a 10-year low in 2025, limited partners continue to invest in Lux Capital [1] Investment Focus - The firm has a history of investing in defense technologies, which have become highly sought after due to recent geopolitical shifts [2] - Lux was an early investor in Anduril, valued at $30.5 billion, and Applied Intuition, valued at $15 billion, both of which have secured significant contracts with the Pentagon [2] AI Investments - Lux has made early investments in AI startups prior to the industry's rapid growth following the launch of ChatGPT [3] - Notable early-stage AI investments include Hugging Face, Runway AI, and MosaicML, the latter of which was acquired by Databricks for $1.3 billion in 2023 [3] Exits and Performance - The firm has achieved significant exits from investments, including Recursion Pharmaceuticals, which went public in 2021, and Auris Health, sold to Johnson & Johnson for up to $6 billion in 2019 [4] - The latest fundraising effort has increased Lux's total assets under management to $7 billion [4]

Core Insights - XOMA Royalty Corporation has amended its collaboration with Takeda, regaining a majority of the royalty interest in mezagitamab while diversifying its portfolio through a strategic royalty share transaction [1][2] Summary by Relevant Sections Collaboration with Takeda - The collaboration, originally established in 2006, has been amended to reduce Takeda's royalty and milestone payment obligations related to mezagitamab [1] - XOMA Royalty will now receive low to mid-single-digit royalties and milestone payments across nine development-stage assets in Takeda's externalized assets portfolio [1][2] Financial Implications - Prior to the amendment, XOMA Royalty held a mid-single-digit royalty and $16.25 million in potential milestones for mezagitamab [3] - Post-amendment, XOMA Royalty will retain a low single-digit royalty entitlement and up to $13.0 million in milestones for mezagitamab [3] Development-Stage Assets - The nine development-stage assets include: - **Osavampator**: Developed by Neurocrine Biosciences for major depressive disorder [4] - **Volixibat**: Developed by Mirum Pharmaceuticals for primary sclerosing cholangitis and primary biliary cholangitis [5] - **OHB-607**: A recombinant human IGF-1/IGFBP-3 for preventing bronchopulmonary dysplasia in premature infants, along with other early-stage assets from Oak Hill Bio [6] - **REC-4881**: An investigational MEK1/2 inhibitor for familial adenomatous polyposis, affecting approximately 50,000 people in the U.S. and Europe [7]

Core Insights - Nvidia-related stocks experienced a collective surge, indicating strong market interest and potential investor confidence in the sector [1] Stock Performance - NEBIUS saw an increase of over 6% [1] - Applied Digital and Recursion Pharmaceuticals both rose by more than 4% [1] - CoreWeave experienced a rise of over 3% [1]

格隆汇12月22日｜NEBIUS涨超6%，Applied Digital、Recursion Pharmaceuticals涨超4%，CoreWeave涨 超3%。 来源：格隆汇APP ...

Core Viewpoint - Nvidia holds equity stakes in several public companies, including CoreWeave, which has seen significant stock price growth since going public [2][3] Company Overview - CoreWeave operates as a neocloud, building data centers equipped with GPU clusters and renting access through a cloud-based platform [4][5] - The company has a market capitalization of $44 billion and a gross margin of 49.23% [4] Business Performance - CoreWeave's backlog reached $55.6 billion, reflecting a 271% year-over-year increase [9] - Major customers include OpenAI, which has committed $22.4 billion, and Meta Platforms, with a multiyear deal worth $14.2 billion [10] Market Position - CoreWeave's revenue is projected to rise nearly fourfold over the next two years, with an implied price-to-sales ratio of 2.2 based on expected 2027 revenue [12] - The company's valuation is lower than competitors like Iren and Nebius Group, which trade at 3.3x projected 2027 sales [13] Financial Considerations - CoreWeave has taken on over $13 billion in debt to finance infrastructure buildouts [15] - Nvidia's $6.3 billion deal with CoreWeave provides a safeguard by agreeing to purchase unused capacity, mitigating risks associated with overbuilding [16][17] Investment Thesis - CoreWeave is positioned for long-term success in the AI infrastructure era, supported by a strong backlog, customer acquisition, and strategic alliances [18]

Stock Analysis & Investment Recommendations - A caller discusses a stock they bought a year and a half ago that has been consistently dropping after earnings reports, but believes it will turn around [2] - The caller mentions the company received $30 million from Roach Genante in October and has $785 million in cash [2] - A major announcement regarding drug trials is expected on December 8th, which the caller anticipates will be favorable [2] - Nat Khan, described as a genius, will take over Recursion Pharmaceuticals on January 1st, with expectations of a banner year in 2026 [3] - The host acknowledges the stock's "horrendous" performance and categorizes it as speculative, advising caution despite the company's financial resources [3][4] - Regarding New Scale Power SMR in the nuclear sector, the recommendation is to scale out on the way up, selling portions at $25, $27, and $30, and eventually getting rid of all of it [5] Company & Industry Specifics - GE Vernova is highlighted as a company that knows how to build nuclear power plants [5] - Five Below is mentioned as a bargain retailer undergoing a turnaround, with an analysis to determine if the company can sustain its performance or if the price is too high [6] Program Information - The Lightning Round is sponsored by Charles Schwab [6] - Viewers are encouraged to follow Jim Kramer on X (formerly Twitter), and can send questions via Twitter using madmentions, email to madmoney@cnbc.com, or call 1-800-743-CNBC [6] - Missed segments can be found at madmoney.cnbc.com [7]

Core Insights - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 1% on Monday [1] - WW International, Inc. announced a partnership with Amazon Pharmacy to enhance access to weight management medications, resulting in a significant rise in its stock price [1] Company Performance - WW International shares surged by 12.5%, reaching $30.28 on Monday following the announcement of the partnership [2] - Replimune Group, Inc. saw its shares jump by 103.5% to $9.16 after the FDA accepted its Biologics License Application resubmission for RP1 [4] - Celcuity Inc. experienced a 46.1% increase in stock price to $75.93 after presenting positive Phase 1 data at ESMO 2025 [4] - American Battery Technology Company shares rose by 26.3% to $6.13 [4] - Canaan Inc. gained 25% to $2.0007 [4] - Datavault AI Inc. increased by 21% to $2.1650 following a partnership announcement [4] - GRAIL, Inc. jumped 21% to $94.29 after announcing a $325 million private placement financing [4] - Other notable gains included Bit Digital, Inc. at 21% to $4.4500, Kodiak Sciences Inc. at 17.4% to $16.56, and Recursion Pharmaceuticals, Inc. at 17% to $6.84 [4]

Group 1 - Nvidia-related stocks experienced a collective increase on October 15, with Recursion Pharmaceuticals rising over 12% [1] - WeRide saw an increase of more than 7% [1] - CoreWeave's stock rose by over 4% [1]

Investment Recommendations - Suggests buying Dutch Bros (BROS) stock, currently at $53, with a plan to buy more in the $40s, anticipating it won't drop to the $30s [2] - Highlights American Bitcoin (ABTC) as a highly speculative investment with no current earnings, emphasizing the risk of losing the entire investment [4][5] - Expresses skepticism about Recursion Pharmaceuticals, an AI-powered drug discovery stock backed by Nvidia, citing its poor performance and the need for a proof of concept before recommending investment [6][7][8] - Awaits a "bounce" in Republic Services (RSG) and Waste Management (WM) stocks, despite their strong cash flow and dividend growth, due to rising long-term interest rates and pressure on infrastructure spending [8][9] Market Commentary - Notes the speculative froth coming out of Dutch Bros stock, which has fallen from $86 to $53 [2] - Mentions the potential impact of rising long-term interest rates and infrastructure spending pressure on Republic Services [8]